Alzheimer's disease is one of the most common causes of dementia in older age. It causes progressive loss of cognitive functions, memory, orientation, and identity. Although science is still searching for a definitive treatment, there is growing interest in substances that can slow neurodegeneration or mitigate accompanying inflammatory manifestations. One such substance is beta-caryophyllene (BCP).
What Science Says
Studies from recent years show that CB2 receptor activation using BCP can lead to reduced neuroinflammation, oxidative stress, and neuronal apoptosis. These three mechanisms play a fundamental role in the progression of Alzheimer's disease.
Cheng et al. (2014) demonstrated that BCP reduces inflammatory markers in the brain, acts against oxidative stress, and improves cognitive functions. Gertsch et al. (2008) confirmed that BCP is a selective CB2 receptor agonist making it one of the few substances outside cannabis that can directly influence this system.
What Are the Benefits?
BCP appears as a neuroprotective substance that can slow inflammatory damage to neurons, act against oxidative stress, support regeneration and survival of brain cells—all without psychoactive effects or legislative complications. It has high absorbability (up to 60%) and is recognized as safe for use (GRAS certification according to FDA).
— Jiří Stabla